Evidence map›Paper›PMID 37664009›Full record

ArticleEngineering in life sciences2023

Evaluation of restricted access media for the purification of cell culture-derived Orf viruses.

Keven Lothert, Yasmina M J Harsy, Patrick Endres, Egbert Müller, Michael W Wolff

Abstract read
In one paragraph

Article in Engineering in life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keven LothertInstitute of Bioprocess Engineering and Pharmaceutical Technology University of Applied Sciences Mittelhessen (THM) Giessen Germany.ORCID https://orcid.org/0000-0002-8930-9834
Yasmina M J HarsyInstitute of Bioprocess Engineering and Pharmaceutical Technology University of Applied Sciences Mittelhessen (THM) Giessen Germany.
Patrick EndresTosoh Bioscience GmbH, Separations Business Unit - Europe Griesheim Germany.
Egbert MüllerTosoh Bioscience GmbH, Separations Business Unit - Europe Griesheim Germany.
Michael W WolffInstitute of Bioprocess Engineering and Pharmaceutical Technology University of Applied Sciences Mittelhessen (THM) Giessen Germany.ORCID https://orcid.org/0000-0001-7443-3122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, multimodal chromatography using restricted access media (RAM) for the purification of nanoparticles, such as viruses has regained increasing attention. These chromatography resins combine size exclusion on the particle shell and adsorptive interaction within the core. Accordingly, smaller process-related impurities, for example, DNA and proteins, can be retained, while larger product viruses can pass unhindered. We evaluated a range of currently available RAM, differing in the shells' pore cut-off and the core chemistry, for the purification of a cell culture-derived clarified model virus, namely the Orf virus (ORFV). We examined impurity depletion and product recovery as relevant criteria for the evaluation of column performance, as well as scale-up robustness and regeneration potential for evaluating a multiple use application. The results indicate that some columns, for example, the Capto Core, enable both a high DNA and protein removal, while others, for example, the Monomix Core 60 (MC60), are more suitable for DNA depletion. Furthermore, column regeneration is facilitated by using columns with larger shell pores (5000 vs. 700 kDa) and weaker binding interactions (anion exchange vs. multimodal). According to these findings, the choice of RAM resins should be selected according to the respective feed sample composition and the planned number of application cycles.

Indexed as

downstream processingmultimodal chromatographyparapoxvirus ovisplatform technologyviral vector

Identifiers

PMID37664009
PMCPMC10472920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.